A Sympathetic Treatment for Obesity

Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahu et al. (2020) describe the effect of a new derivative of AMPH, PEGyAMPH, a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects.